These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system ...

European shares were mostly higher today. The eurozone's STOXX 600 rose 0.3%, Germany's DAX 40 gained 0.2% and France's CAC 40 climbed 0.3%. Spain's IBEX 35 Index fell 0.1%, while London's FTSE 100 ...

Kadimastem’s attempt to vault onto Nasdaq is picking up momentum, with shareholders signing off on a merger with NLS Pharmaceutics that would enable the cell therapy developer to recover from last ...

ZURICH and NESS ZIONA, Israel - Shareholders of Kadimastem Ltd. (TASE: KDST), a cell therapy company currently valued at $18.19 million, have approved a merger with Swiss biopharmaceutical firm NLS ...

NLS Pharmaceutics (NLSP) and Kadimastem, a clinical-stage cell therapy company specializing in the treatment of neurodegenerative diseases and ...

NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and ...

NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system ...

The Ahmedabad -based Patel, whose Zydus Group runs a chain of multi-specialty hospitals, further said, “We are taking a leap ...

Innovation from India will bring critical access to affordable healthcare and empower people to lead healthier and more ...

Chairman of Zydus Lifesciences Pankaj Patel on Sunday expressed his gratitude upon being bestowed with the Padma Bhushan and ...

NLS Pharmaceutics AG (NLSP) stock has hit a 52-week low, trading at $1.73, with a market capitalization of just $2.94 million ...